For about twenty years, scientists have been working on a radical idea: what if a drug could make the body destroy a harmful protein instead of just blocking it? On May 1, 2026, this idea finally became reality.
The U.S. Food and Drug Administration approved vepdegestrant, sold as Veppanu, for adults with advanced breast cancer that is difficult to treat. It is the first drug of its kind, called a PROTAC, that the FDA has ever approved. The drug was developed by Arvinas with Pfizer.
Veppanu works in a new way. Most cancer drugs stop a problem protein from working. Veppanu does something different. It has two ends. One end catches the cancer protein, called the estrogen receptor. The other end tells the cell's cleaning system to destroy the protein completely. The cell then removes it entirely.
In a trial with 624 patients, those taking vepdegestrant lived longer before their cancer grew again compared to those taking an older drug. Tumors shrank in 19 percent of patients on Veppanu, compared to only 4 percent on the older medicine.
The drug is a single pill taken once a day. Common side effects include low white blood cells, tiredness, and nausea. The FDA also approved a blood test to identify which patients will benefit most from this new treatment.
For Arvinas, a small company based in New Haven, this is their first drug approved by the FDA. Scientists have been researching this technology since 2001, and many doubted it would ever work as medicine. Now, researchers are exploring similar drugs for other serious diseases like Alzheimer's.